Vitamin B2 (Riboflavin): A Comprehensive Reference
1. Identity, Chemistry, and Natural Sources
Names and Chemical Identity
Riboflavin, also known as vitamin B2, is one of the B vitamins, all of which are water soluble. Its systematic chemical name is 7,8-dimethyl-10-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]benzo[g]pteridine-2,4(3H,10H)-dione. The "flavin" portion of riboflavin gives it a bright yellow color, an attribute that helped lead to its discovery as a vitamin. Riboflavin was first isolated as the water-soluble, yellow-green, fluorescent "lactochrome."
Natural Sources
Riboflavin is naturally present in some foods, added to some food products, and available as a dietary supplement. The major food sources of riboflavin are dairy products, especially milk, and meat and fish; most plants contain only small amounts of riboflavin. Some of the best dietary sources of riboflavin include milk, eggs, organ meats, soybeans, spinach, broccoli, mushrooms, wild rice, whole grains, wheat germ, almonds, and brewer's yeast.
Since the processing of grains results in significant loss of vitamin B2, white flour, bread, and breakfast cereals are often enriched or fortified with riboflavin in the United States. Riboflavin is also added to pastas, baby foods, and meal replacement products and used as a food coloring agent. Riboflavin enrichment of flour is mandated in the US and some other countries with the aim of restoring the losses of the vitamin during milling and refining processes.
Bacteria in the gut can produce small amounts of riboflavin, but not enough to meet dietary needs.
Supplement and Pharmaceutical Forms
Riboflavin tablets are available in 25, 50, and 100 mg doses. Oral supplementation is preferred; injections are reserved for patients who cannot tolerate oral therapy. The primary active pharmaceutical forms are free riboflavin and riboflavin 5′-phosphate (also called flavin mononucleotide, or FMN). The United States Food and Drug Administration (FDA) has approved the ophthalmic formulation of riboflavin 5′-phosphate in treating corneal ectasia post-refractive surgery and managing progressive keratoconus.
2. Historical Discovery and Traditional Use
The first observation of a pigment in milk with yellow-green fluorescence can be traced to the English chemist Alexander Wynter Blyth in 1872, but it was not until the early 1930s that the substance was characterized as riboflavin.
In the early 1900s, the pioneer work of Christiaan Eijkman, Frederick Hopkins, Casimir Funk, Elmer McCollum, and others firmly established the existence of a new class of essential nutrients, and in only five decades, paved the way to the isolation of more than a dozen vitamins as pure chemical substances. In 1927, it was recognized that the so-called vitamin B complex contained two different components: the heat-labile antineuritic factor, vitamin B1 (thiamine), and vitamin B2 (riboflavin), a more heat-stable factor required by the rat for the maintenance of growth and the prevention of skin lesions.
In 1933, the Heidelberg University team including Paul György, Richard Kuhn, and Theodore Wagner-Jauregg was successful for the first time in the isolation and purification of vitamin B2, using the growth response of rats fed a purified diet as an assay. The existence of a heat-stable growth factor in yeast extracts was first discovered by Emmett and Luros in 1920.
As there is no classical nutritional disease directly attributable to riboflavin deficiency (in contrast to thiamin and beriberi, or niacin and pellagra), it was the growth-stimulating properties of food extracts given to young rats that provided the tool with which to investigate and eventually extract riboflavin. The vitamin was not identified through the treatment of a distinctive clinical disease but rather through laboratory investigation of nutritional growth factors. Subsequent to the discovery of thiamin was the discovery of a more heat-stable factor that was named vitamin B2, or riboflavin.
3. Key Constituents, Active Compounds, and Mechanisms of Action
Coenzyme Forms: FMN and FAD
Riboflavin is an essential component of two major coenzymes, flavin mononucleotide (FMN; also known as riboflavin-5′-phosphate) and flavin adenine dinucleotide (FAD). These coenzymes play major roles in energy production; cellular function, growth, and development; and metabolism of fats, drugs, and steroids.
Riboflavin functions as a coenzyme in numerous redox reactions. Riboflavin is an essential component of flavoproteins, which are coenzymes involved in many metabolic pathways of carbohydrate, lipid, and protein metabolism. Flavoproteins aid in the transfer of electrons in the electron transport chain.
Conversion of Other Vitamins
The conversion of the amino acid tryptophan to niacin (sometimes referred to as vitamin B3) requires FAD. Similarly, the conversion of vitamin B6 to the coenzyme pyridoxal 5′-phosphate needs FMN. Furthermore, the functions of other B-vitamin coenzymes, such as vitamin B6 and folate, are dependent on the actions of flavoproteins.
Homocysteine Metabolism and MTHFR
The flavoprotein methylenetetrahydrofolate reductase (MTHFR) plays a pivotal role in folate-mediated one-carbon metabolism. MTHFR converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the cofactor form necessary for the re-methylation of homocysteine to methionine. Riboflavin regulates circulating levels of homocysteine, an amino acid that enters the diet from animal protein foods like meat. High levels in the blood are a risk factor for cardiovascular disease (CVD). Riboflavin works with other B vitamins like B6, folate, and B12 to break down homocysteine in the body.
Absorption and Storage
A reasonable estimation of bioavailability is approximately 95 percent of food flavin, up to a maximum of about 27 mg absorbed per single meal or dose. The rate of absorption is proportional to intake, and it increases when riboflavin is ingested along with other foods and in the presence of bile salts. The body does not store riboflavin in large amounts; only small reserves exist in the liver, heart, and kidneys. Most riboflavin is used immediately and not stored in the body, so excess amounts are excreted in the urine. An excess of dietary riboflavin, usually from supplements, can cause urine to become bright yellow.
Riboflavin is sensitive to light; if the vitamin is exposed to too much light, it can be deactivated from its usable form. This is why milk is now typically sold in cartons or opaque plastic containers to block light.
4. Scientific Evidence by Area of Use
4.1 Riboflavin Deficiency (Ariboflavinosis)
The signs and symptoms of riboflavin deficiency (also known as ariboflavinosis) include skin disorders, hyperemia and edema of the mouth and throat, angular stomatitis (lesions at the corners of the mouth), cheilosis (swollen, cracked lips), hair loss, reproductive problems, sore throat, itchy and red eyes, and degeneration of the liver and nervous system. Severe riboflavin deficiency can impair the metabolism of other nutrients, especially other B vitamins, through diminished levels of flavin coenzymes. Anemia and cataracts can develop if riboflavin deficiency is severe and prolonged.
Riboflavin deficiency is most often accompanied by other nutrient deficiencies, and it may lead to deficiencies of vitamin B6 and niacin in particular. Riboflavin deficiencies often occur in tandem with deficiencies in other water-soluble vitamins, as well as in the elderly and individuals with chronic alcoholism, liver disease, eating disorders, diabetes, and inflammatory bowel disease.
Evidence strength: The role of riboflavin in correcting ariboflavinosis is well-established and supported by extensive clinical and observational evidence. Oral supplementation is the standard treatment and effectively reverses the characteristic signs and symptoms.
4.2 Migraine Prophylaxis
Riboflavin plays a vital role in producing energy in mitochondria and reducing inflammation and oxidative stress. Migraine pathogenesis includes neuroinflammation, oxidative stress, and mitochondrial dysfunction. Therefore, riboflavin is increasingly being recognized for its preventive effects on migraines.
Seven studies (including three RCTs) in adults have evaluated the role of riboflavin in preventing adult migraines. The dose of riboflavin was 400 mg, except in one case (100 mg). All studies demonstrated the effectiveness of riboflavin.
A 2025 systematic review and dose-response meta-analysis included 12 trials with a total sample size of 749. The dose-response meta-analysis revealed a significant linear relationship, showing that increasing riboflavin intake up to 400 mg/day was associated with greater reductions in migraine frequency and duration, without evidence of a threshold effect (P < 0.001).
In pediatric populations, patients treated with riboflavin had a reduction in headache frequency, use of acute medications, and days of school missed. Riboflavin prophylaxis also reduced migraine intensity and duration. Riboflavin is recommended as a safe, inexpensive, and effective nutraceutical in the treatment of pediatric migraine.
Because some people appear to benefit from the supplements, they are inexpensive, and side effects have been minimal, the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society concluded that riboflavin is probably effective for preventing migraine headaches and approved its use as a complementary treatment.
Evidence strength: Moderate to good. The body of evidence from multiple RCTs and a 2025 meta-analysis supports riboflavin's effectiveness as a migraine prophylactic, particularly at doses of 400 mg/day. Limitations include relatively small individual trial sizes and heterogeneity in outcome measures. There is no concrete evidence supporting its use because the link between riboflavin and migraines and the underlying mechanisms remains obscure, though the clinical signal is consistent.
4.3 Cardiovascular Disease and Homocysteine
Plasma total homocysteine (tHcy) is a risk factor for cardiovascular disease. tHcy concentrations are partly determined by folate, cobalamin, and vitamin B6 status, and methylenetetrahydrofolate reductase (MTHFR) and other flavoenzymes are important for the biotransformation of these vitamins. This motivates the investigation of the possible relationship between riboflavin status and tHcy.
In a cross-sectional study of 423 healthy blood donors, tHcy was 1.4 µmol/L higher in the lowest compared with the highest riboflavin quartile. The riboflavin-tHcy relationship was modified by genotype (P = 0.004) and was essentially confined to subjects with the C677T transition of the MTHFR gene. Plasma riboflavin is an independent determinant of plasma tHcy.
Individuals with a certain genetic variation (polymorphism) in MTHFR may have an increased risk of developing high blood pressure, cardiovascular disease, and cancer. In hypertensive individuals with the MTHFR c.677C>T polymorphism (homozygotes), low-dose riboflavin supplementation lowers both homocysteine concentration and blood pressure.
Despite strong epidemiological and mechanistic support, the translation of homocysteine-lowering interventions into clinical benefit remains controversial. Although elevated homocysteine remains a reproducible biomarker of cardiovascular risk, current evidence does not support routine intervention in unselected populations.
Evidence strength: Preliminary to moderate. The effect of riboflavin on homocysteine, particularly in individuals with the MTHFR C677T polymorphism, is supported by clinical evidence. However, whether this biochemical effect translates into reduced cardiovascular events has not been definitively established in randomized controlled trials. Evidence is strongest in the genetically defined subgroup.
4.4 Anemia and Iron Metabolism
Research in animals suggests that riboflavin deficiency may impair iron absorption, increase intestinal loss of iron, and/or impair iron utilization for the synthesis of hemoglobin. In humans, low dietary intake of riboflavin has been associated with an increased risk for anemia, and improving riboflavin nutritional status has been found to increase circulating hemoglobin levels. Correction of riboflavin deficiency in individuals who are both riboflavin and iron deficient improves the response of iron-deficiency anemia to iron therapy.
Evidence strength: Moderate for the association between riboflavin deficiency and anemia. Human studies demonstrate that riboflavin repletion improves hemoglobin levels in deficient individuals and potentiates the response to iron therapy. Evidence is less robust for populations with adequate riboflavin status.
4.5 Cataracts
Lenticular reduced glutathione, which is diminished in all forms of human cataract, requires flavin adenine dinucleotide as a coenzyme for glutathione reductase. Deficiency of riboflavin, a precursor of flavin adenine dinucleotide, has been believed by some to be associated with cataract formation. Riboflavin does appear to play an essential role in prevention of cataract formation, though the supporting clinical evidence is not conclusive. There is some evidence predominantly from observational studies that suggests higher riboflavin status might be beneficial; however, more evidence from well-designed, randomized controlled trials is needed to confirm a role for riboflavin in the prevention of cataracts.
Evidence strength: Weak to preliminary in humans. The mechanistic rationale is plausible, but clinical evidence remains primarily observational. No large RCTs have conclusively demonstrated that riboflavin supplementation prevents cataracts.
4.6 Corneal Collagen Cross-Linking (Ophthalmic Use)
Corneal collagen cross-linking (CXL) is a therapeutic intervention that utilizes riboflavin photochemical activation with ultraviolet-A (UV-A) light to induce covalent cross-links within the stromal corneal fibers, effectively increasing corneal biomechanical stability and halting progressive ectasia. The method was introduced in the late 1990s in Germany at the University of Dresden. The cross-linking method using the Avedro system was approved by the US Food and Drug Administration (FDA) on 18 April 2016, based on three prospective, multicenter, randomized clinical trials for keratoconus and other corneal ectasias.
Corneal collagen cross-linking (CXL) with riboflavin and ultraviolet A (UVA) radiation is the first therapeutic modality that appears to arrest the progression of keratoconus and other corneal ectasias. Riboflavin is central to the process, acting as a photosensitizer for the production of oxygen species. Clinical follow-up is limited to 5–10 years, but suggests sustained stability and enhancement in corneal shape.
Corneal cross-linking (CXL) using riboflavin and ultraviolet A (UVA) light has become a useful treatment option for not only corneal ectasias such as keratoconus, but also a number of other corneal diseases. Riboflavin is a photoactivated chromophore that plays an integral role in facilitating collagen crosslinking.
Evidence strength: Strong for the ophthalmic indication. The procedure has FDA regulatory approval and is supported by multiple prospective multicenter randomized controlled trials. This is the strongest area of clinical evidence for riboflavin as a therapeutic agent.
4.7 Cancer — Preliminary and Observational Evidence
Riboflavin, as FAD, is a cofactor for MTHFR and provides evidence for some interactions among riboflavin status, folate status, and genotype in determining plasma homocysteine, a functional marker of folate status. The MTHFR C677T polymorphism appears to interact with folate and riboflavin in modulating cancer risk, and this interaction varies according to the cancer site.
Animal studies show that brain and heart disorders and some cancers can develop from long-term riboflavin deficiency.
Evidence strength: Preliminary. Evidence for riboflavin's role in cancer is largely from animal studies, in vitro research, and observational epidemiological data. No large RCTs have established a causal role for riboflavin supplementation in cancer prevention in humans.
4.8 Neonatal Phototherapy
Off-label uses of oral riboflavin include migraine prophylaxis, neonates undergoing phototherapy, and addressing antiretroviral-induced lactic acidosis. Phototherapy used to treat neonatal jaundice can degrade riboflavin; however, routine riboflavin supplementation in this setting remains an off-label indication without strong RCT evidence.
5. Body Systems and Health Areas
Riboflavin's coenzyme roles span multiple physiological systems:
- Energy metabolism: Riboflavin is a key component of coenzymes involved with the growth of cells, energy production, and the breakdown of fats, steroids, and medications.
- Nervous system: Riboflavin helps to maintain the integrity of mucous membranes, skin, eyes, and the nervous system.
- Hematopoietic system: Riboflavin is essential for cell growth, metabolism, and the production of red blood cells.
- Cardiovascular system: Through its role as a cofactor for MTHFR, riboflavin participates in homocysteine metabolism relevant to cardiovascular risk, particularly in carriers of the MTHFR C677T variant.
- Ocular system: Riboflavin is used both nutritionally (where its deficiency is linked to cataracts) and therapeutically (in corneal cross-linking procedures for keratoconus).
- Skin and mucous membranes: Deficiency manifests as skin disorders, angular stomatitis, and cheilosis.
- Hepatic and endocrine metabolism: FAD and FMN coenzymes play roles in metabolism of fats, drugs, and steroids.
6. Recommended Intakes and Dosages Reported in Studies
Dietary Reference Values (United States)
The Recommended Dietary Allowance (RDA) for men and women ages 19+ years is 1.3 mg and 1.1 mg daily, respectively. For pregnancy and lactation, the amount increases to 1.4 mg and 1.6 mg daily, respectively.
The median intake of riboflavin from food in the United States and two Canadian populations was estimated to be approximately 2 mg/day for men and 1.5 mg/day for women. The ninety-fifth percentile of U.S. intake from both food and supplements ranged from 4 to 10 mg/day.
Therapeutic Dosages in Clinical Studies
- Migraine prophylaxis in adults: Seven studies (including three RCTs) evaluated riboflavin for preventing adult migraines. The dose used was 400 mg/day, except in one case (100 mg).
- Migraine dose-response: A dose-response meta-analysis revealed a significant linear relationship, showing that increasing riboflavin intake up to 400 mg/day was associated with greater reductions in migraine frequency and duration, without evidence of a threshold effect.
- Safety ceiling in trials: No adverse effects have been reported from high riboflavin intakes from foods or supplements up to 400 mg daily for at least 3 months.
Upper Intake Level
The evidence on adverse effects is not sufficient to set a Tolerable Upper Intake Level (UL) for riboflavin. A toxic level of riboflavin has not been observed from food sources and supplements. The gut can only absorb a limited amount of riboflavin at one time, and an excess is quickly excreted in the urine. Therefore, a Tolerable Upper Intake Level for riboflavin has not been established.
7. Safety Considerations and Drug Interactions
General Safety Profile
Riboflavin has high water solubility and limited absorption. High-dose riboflavin does not cause toxicity as excess riboflavin is excreted in the urine. A toxic level of riboflavin has not been observed from food sources and supplements. The gut can only absorb a limited amount of riboflavin at one time, and an excess is quickly excreted in the urine.
When riboflavin is taken in excess amounts in supplement form, the excess will be excreted through the kidneys and appear in the urine. Although the color may alarm users, it is harmless.
Populations at Elevated Risk of Deficiency
Individuals who follow a diet low in meat and milk, which are considered the best sources of riboflavin, and certain specific groups of people, such as pregnant women, children, and athletes, may be more susceptible to this deficiency. Other risk factors for riboflavin deficiency include pregnancy, poverty, old age, depression, breastfeeding, phototherapy, and poor cognition.
Even in high-income countries, inadequate intake occurs among older adults and adolescents despite food availability. Chronic alcohol consumption impairs riboflavin status through multiple mechanisms.
Individuals consuming mainly plant-based diets may be at risk for riboflavin deficiency. According to the Celiac Disease Foundation, people following a gluten-free diet (i.e., who do not eat enriched wheat foods) may also suffer riboflavin deficiency.
Phenothiazines and Tricyclic Antidepressants
Chlorpromazine, a phenothiazine derivative, and imipramine and amitriptyline, both tricyclic antidepressants, each inhibited the incorporation of [14C]riboflavin into [14C]FAD in liver, cerebrum, cerebellum, and heart. Chlorpromazine, imipramine, and amitriptyline in vitro inhibited hepatic flavokinase, the first of two enzymes in the conversion of riboflavin to FAD. Phenothiazine derivatives like the anti-psychotic medication chlorpromazine (Thorazine), and tricyclic antidepressants inhibit the conversion of riboflavin to FAD and FMN, as do the anti-malarial medication quinacrine, and the cancer chemotherapy agent adriamycin.
Anticonvulsants
Long-term use of the anticonvulsant phenobarbitol may increase destruction of riboflavin by liver enzymes, increasing the risk of deficiency.
Oral Contraceptives
Several early reports indicated that women taking high-dose oral contraceptives had diminished riboflavin biomarker status. However, when investigators controlled for dietary riboflavin intake, no differences between users of oral contraceptives and non-users were found.
Chronic Alcohol Consumption
Chronic alcohol consumption has been associated with riboflavin deficiency. In rats chronically fed alcohol, the inhibition of riboflavin transporters caused impairment in intestinal absorption and renal re-uptake of the vitamin.
Assessment of Status
Blood levels and urinary excretion are not sensitive markers of riboflavin deficiency, and the preferred method for assessing riboflavin status is stimulation of the FAD-dependent erythrocyte glutathione reductase. The results express an activation coefficient—EGRAC (erythrocyte glutathione reductase activity coefficient)—such that the poorer the riboflavin status, the higher the activation coefficient. An EGRAC above 1.3 indicates riboflavin deficiency.
References
Volver